🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML NCT05024552Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Gilteritinib, Vyxeos CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site📍 Camden Roger Strair · Tests: Soursop tea A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites📍 Beijing📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG-115, Azacitidine, Cytarabine Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247EARLY Phase 11 site📍 Beijing Peking University People's Hospital · Tests: JD123 injection Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS NCT06680752Phase 1, Phase 23 sites📍 Charlotte📍 Winston-Salem📍 Houston ARCE Therapeutics, Inc. · Tests: ARD103, Cyclophosphamide, Fludarabine PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML NCT05105152Phase 11 site📍 Seattle Seattle Children's Hospital · Tests: SC-DARIC33 IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. NCT06713837Phase 347 sites📍 Brno📍 Hradec Králové📍 Olomouc Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: High intensity therapies, Low intensity therapies Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT04774393Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine and Cedazuridine, Enasidenib, Ivosidenib, Venetoclax HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) NCT03113643Phase 13 sites📍 Duarte📍 Boston📍 Houston Dana-Farber Cancer Institute · Tests: Azacitidine, SL-401, Venetoclax First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) NCT07384715Phase 16 sites📍 Aarhus📍 Copenhagen📍 Barcelona Genmab · Tests: GEN3018 Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia NCT07014449Phase 11 site📍 Hangzhou Hangzhou Weben Pharma Co., Ltd · Tests: WBC100 QD SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: supCD7 CART cells Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome NCT03661307Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine, Quizartinib, Venetoclax A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome NCT06501196Phase 113 sites📍 Duarte📍 Los Angeles📍 Palo Alto BlossomHill Therapeutics · Tests: BH-30236, Venetoclax CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML NCT07347418Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD64 CAR T Cells Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788Phase 145 sites📍 Gilbert📍 Los Angeles📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia NCT03214562Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cytarabine, Filgrastim, Fludarabine, Idarubicin, Pegfilgrastim Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT03850574Phase 1, Phase 234 sites📍 Birmingham📍 Duarte📍 Irvine Aptose Biosciences Inc. · Tests: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT06871410Phase 11 site📍 Buffalo Roswell Park Cancer Institute · Tests: Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide Phase I Study of FXS0683 in the Treatment of Blood Tumors NCT07616089Phase 11 site📍 Tianjin Shanghai Fosun Pharmaceutical Industrial Development Co. Lt… · Tests: FXS0683 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Master Framework For Relapse or Refractory Acute Myeloid Leukemia NCT06459024n/a40 sites📍 Aachen📍 Greifswald📍 Halle Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Registration into the STREAM platform Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML NCT04501120Phase 1, Phase 212 sites📍 Beijing📍 Chongqing📍 Guangzhou Ascentage Pharma Group Inc. · Tests: Lisaftoclax (APG-2575), Reduced-dose HHT, standard-dose HHT, Azacitidine, Lisaftoclax (APG-2575) A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) NCT07306832Phase 114 sites📍 Palo Alto📍 Atlanta📍 Valhalla AbbVie · Tests: Pivekimab Sunirine Tazemetostat and Palbociclib With CPX-351for R/R AML NCT05627232Phase 11 site📍 Philadelphia Thomas Jefferson University · Tests: Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection,… CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML NCT05945849Phase 11 site📍 Philadelphia University of Pennsylvania · Tests: CD33KO-HSPC; CART33
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy